NRSNNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NRSNW
NeuroSense Therapeutics Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$2.67−0.40 (-13.19%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
NeuroSense Therapeutics has not reported a dividend
No dividend per share appears in NeuroSense Therapeutics's annual filings since fiscal 2018.